Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PainReform ( (PRFX) ) has issued an update.
On January 6, 2026, PainReform Ltd. held its Adjourned Annual General Meeting of Shareholders, at which investors approved all six proposals presented, each receiving the required majority vote. The approvals, following an earlier notice and proxy process initiated in November 2025, clear the way for the company to implement its planned corporate and governance actions as set out to shareholders, reinforcing management’s mandate and shaping the company’s operational and strategic direction for the coming year.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is driven primarily by very weak financial performance (minimal revenue, widening losses, and worsening cash burn with a shrinking equity cushion). Technicals also weigh on the score due to a clear downtrend versus key moving averages, partially offset by oversold indicators. Valuation contributes little support given negative earnings and no dividend yield.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform Ltd. is an Israel-based company that reports as a foreign private issuer in the United States and is listed under SEC file number 001-39481, indicating its participation in the U.S. capital markets and regulatory framework.
Average Trading Volume: 319,539
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.65M
See more data about PRFX stock on TipRanks’ Stock Analysis page.